 |
Japan Antipsychotic Drugs market, by drug class type, 2014 - 2025 (USD
Million)
|
The global antipsychotic drugs market is expected to reach USD 14.4
billion by 2025, according to a new report by Grand View Research, Inc. The
continuous development of better next-generation products to overcome adverse
effects and unwanted reactions of existing products is creating demand for
newer products. This factor is anticipated to propel the market.
Rapid growth of antipsychotics can be attributed to the rising
prevalence of psychosis and other mental disorders. Governments are focused on
creating awareness regarding mental health and psychological illnesses, which
is further anticipated to drive the demand for antipsychotics. Government
bodies in collaboration with major players conduct social programs to break the
stigma related to psychotic disorders that exists in the society.
Adverse effects of antipsychotics, such as insomnia, dry mouth,
drowsiness, and blurred vision, are expected to affect the growth by decreasing
the level of acceptance in patients. In addition, the possibility of dependency,
habit formation, or addiction is affecting the adoption of these drugs.
Established brands such as, Zyprexa lost patent protection in October
2011, followed by Seroquel and Risperdal in 2012, which hampers the market
growth for these drugs. Also, the entry of generic versions of these products
slowed the growth of the already existing brands.
Full
Research Report On Antipsychotic Drugs Market Analysis:
Further Key Findings From the Study Suggest:
·
The growing prevalence of mental disorders,
increased investments on R&D, and rising awareness regarding these
conditions are augmenting the growth of the market.
·
The first-generation of antipsychotics have
serious adverse effects and are very rarely used, hence they hold negligible
share in the market.
·
The second-generation segment of drugs
accounted for the largest share in 2015 and are anticipated to further expand
during the forecast period despite the adverse effects
·
As of January 2016, the third-generation
segment has only one approved product, Abilify. It has negligible adverse
effects and is expected to be the fastest growing segment over the forecast
period
·
In 2015, North America dominated the global
space with the largest revenue share owing to rising prevalence of mental
illnesses
·
Asia Pacific is expected to emerge as the
fastest growing region during the forecast period, mainly due to growing social
awareness regarding mental disorders and improving access to treatment
·
Some of the major players in this market
are Johnson & Johnson; Pfizer, Inc.; Eli Lilly & Co.; and Bristol-Myers
Squibb
View More Reports
Of This Category By Grand View Research At: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the antipsychotic drugs market by drug
class, application, and region:
Antipsychotics Drug Class
Outlook (Revenue, USD Million; 2014 - 2025)
·
First Generation
·
Second Generation
·
Third Generation
Antipsychotics Application
Outlook (Revenue, USD Million; 2014 - 2025)
·
Schizophrenia
·
Bipolar disorder
·
Unipolar depression
·
Dementia
·
Others
Antipsychotics Regional
Outlook (Revenue, USD Million; 2014 - 2025)
·
North America
o U.S.
o Canada
·
Europe
o Germany
o UK
·
Asia Pacific
o China
o Japan
·
Latin America
o Mexico
o Brazil
·
MEA
o South Africa
Access Full Press Release of this Report: https://www.grandviewresearch.com/press-release/global-antipsychotic-drugs-market
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more information: https://www.grandviewresearch.com/
